SCHEMBL2219783

SCHEMBL2219783

CCCCC(C(N)=O)N1C(=O)C=CC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.43
CA1 P00915 3/20 0.43
MGLL Q99685 5/20 0.38
PTGS1 P23219 3/20 0.38
PTGS2 P35354 3/20 0.38
FAAH O00519 2/20 0.38
LMNA P02545 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
ALDH1A1 P00352 3/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723987 0.84 KMT2A (0.36) CA2CA1PTGS1PTGS2LMNA
SCHEMBL43970 0.84 PTPN1 (0.42) CA2MGLLPTGS1PTGS2FAAH
SCHEMBL12094816 0.84 MGLL (0.39) CA2CA1MGLLPTGS1PTGS2
SCHEMBL2034675 0.83 MGLL (0.38) CA2CA1MGLLPTGS1PTGS2
Hydrochloric Acid SCHEMBL4277446 0.83 PTPN1 (0.41) CA2MGLLPTGS1PTGS2FAAH
SCHEMBL31723981 0.83 MEN1 (0.35) PTGS1PTGS2ALDH1A1POLBL3MBTL1
SCHEMBL1704808 0.82 CA1 (0.47) CA2CA1MGLLPTGS1PTGS2
SCHEMBL6567846 0.82 LMNA (0.47) CA2CA1MGLLPTGS1PTGS2
SCHEMBL30469023 0.81 CPB2 (0.39) PTGS1PTGS2ALDH1A1POLBL3MBTL1
Hydrochloric Acid SCHEMBL15021865 0.81 CA1 (0.46) CA2CA1MGLLPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1294707-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2003-03-26 EP claimed
WO-2001098290-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
US-20260000777-A1 NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF ARARIS BIOTECH AG (CH) 2026-01-01 US disclosed
US-10266620-B2 Coating agents and coated articles INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2019-04-23 US disclosed
EP-3313522-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES Bayer Pharma Aktiengesellschaft (DE) 2018-05-02 EP disclosed
US-20170081435-A1 COATING AGENTS AND COATED ARTICLES INNOVATIVE SURFACE TECH INC (US) 2017-03-23 US disclosed
US-9539371-B2 Coating agents and coated articles INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2017-01-10 US disclosed
WO-2016207104-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-29 WO disclosed
US-9518118-B2 Anti-HER2 antibodies and immunoconjugates GENENTECH, INC. (US) 2016-12-13 US disclosed
EP-2516567-B1 COATING AGENTS AND COATED ARTICLES INNOVATIVE SURFACE TECHNOLOGIES INC (US) 2016-08-03 EP disclosed
US-20160096893-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH, INC. (US) 2016-04-07 US disclosed
US-20150359944-A1 COATING AGENTS AND COATED ARTICLES INNOVATIVE SURFACE TECHNOLOGIES INC (US) 2015-12-17 US disclosed
EP-2516567-A1 COATING AGENTS AND COATED ARTICLES Innovative Surface Technologies, Inc. (US) 2012-10-31 EP disclosed
US-20120258313-A1 COATING AGENTS AND COATED ARTICLES INNOVATIVE SURFACE TECHNOLOGIES, INC. 2012-10-11 US disclosed
WO-2011084811-A1 COATING AGENTS AND COATED ARTICLES INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2011-07-14 WO disclosed
US-20040242854-A1 Chemical capture reagent GE HEALTHCARE UK LIMITED (GB) 2004-12-02 US disclosed
EP-1402268-A2 CHEMICAL CAPTURE REAGENT Amersham Biosciences UK Limited (GB) 2004-03-31 EP disclosed
WO-2003005026-A2 CHEMICAL CAPTURE REAGENT AMERSHAM BIOSCIENCES UK LIMITED (GB) 2003-01-16 WO disclosed
US-6414013-B1 KINASE INHIBITORS; ANTICANCER AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000777-A1 NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF NECTIN4, IGSF11, VSIG8 CA2 4563/4885CA1 2777/4885MGLL 4137/4885
US-20160096893-A1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES ERBB2, EGFR, ERBB3 CA2 983/4885CA1 2162/4885MGLL 3990/4885
US-20040242854-A1 Chemical capture reagent SPPL2B, PRXL2A, PLG CA2 2273/4885CA1 1247/4885MGLL 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.